Collectively, based on the aggregated melanoma and NSCLC immunotherapeutic cohorts, we discovered that HSPG2 mutations were associated with better tumor immunogenicity and ICI treatment efficacy. The gene discussed is HSPG2; the disease is non-small cell lung carcinoma.